bioAffinity receives China patent allowance for lung cancer diagnostic using flow cytometry

bioAffinity Technologies, Inc.

• CNIPA allowed patent 'System and Method for Determining Lung Health' covering use of antibodies and TCPP porphyrin to label sputum cells for lung cancer detection via flow cytometry.
• China has ~300M smokers (nearly 1/3 of world total) and estimated 1.06M new lung cancer cases in 2022; patent positions CyPath Lung for market expansion.
• CyPath Lung commercial test showed 92% sensitivity, 87% specificity, 88% accuracy in detecting lung cancer in high-risk patients with nodules <20mm; 80% of Stage 1 cancers detected.
• Patent complements bioAffinity's global patent estate including U.S., Japan, Australia, Mexico, Canada, EU.